Conclusion
In the present study, we have investigated the significance of four SLC
polymorphisms on the survival of North Indian lung carcinoma patients
undergoing platinum-based chemotherapy regimens. Briefly, we used
genotyping analysis to see if SLC polymorphism causes differences
in patient clinical outcomes. Our findings imply that SLC polymorphisms
are essential in regulating SLC gene expression, altering
the transporter activity, and affecting overall survival in lung cancer
patients. To the best of our knowledge, this is the first study to
evaluate the role of SLC polymorphism in North Indian lung cancer
patients.According to our findings, genotyping for the SLCpolymorphism could be a valuable tool for predicting which lung cancer
patients will benefit the most from platinum-based chemotherapy.However,
a review of previous papers reveals a plethora of contradictory findings
of the activity of these transporters. Nonetheless, more research into
the role of SLC polymorphisms is needed before a meaningful conclusion
can be reached.
When adopting this technique in the clinic, significant caution should
be exercised to better and personalize therapeutic choices to predict
prognosis and therapy outcomes. Our study evaluates the survival
differences in lung cancer patients with SLC polymorphisms.
Surprisingly, our findings demonstrate a link between SLCpolymorphism and a lower risk of toxicity in north Indian lung cancer
patients.It is well understood that individual toxicities are determined
by the platinum-based chemotherapy regimen used. In the future, further
studies should be explored to analyze the impact of these SLC
polymorphisms on the activity of SLC transporter in order to identify
the involvement of a specific polymorphism in the
pharmacokinetics, pharmacological activity, and toxicity of
chemotherapeutic agents. Such insights could lead to pharmacogenetically
enhanced and individualized drug dosing, correspondingto pharmacokinetic
discrepancies in chemotherapeutic drugs between individuals.